Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.
Bacillus subtilis and some of its close relatives have a long history of industrial and biotechnological applications. Search for antigen expression systems based on recombinant B. subtilis strains sounds attractive both by the extensive genetic knowledge and the lack of an outer membrane, which simplify the secretion and purification of heterologous proteins. More recently, genetically modified B. subtilis spores have been described as indestructible delivery vehicles for vaccine antigens. Nonetheless both production and delivery of antigens by B. subtilis strains face some inherent obstacles, as unstable gene expression and reduced immunogenicity that, otherwise, can be overcome by already available gene technology approaches. In the present review we present the status of B. subtilis-based vaccine research, either as protein factories or delivery vectors, and discuss some alternatives for a better use of genetically modified strains.
Ferreira
Luís C S
LC
Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Av. Prof. Lineu Prestes, 1374, 05508-000 São Paulo, SP, Brazil. lcsf@usp.br
Ferreira
Rita C C
RC
Schumann
Wolfgang
W
D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D015478:Antigens, Heterophile / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D001412:Bacillus subtilis / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines; D004337:Drug Carriers; D015195:Drug Design; D006801:Humans; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification
D000942:Antigens, Bacterial; D015478:Antigens, Heterophile; D001428:Bacterial Vaccines; D004337:Drug Carriers; D011994:Recombinant Proteins